Unraveling Heterogeneity of the Clinical Pharmacogenomic Guidelines in Oncology Practice Among Major Regulatory Bodies

References

• Relling MV , EvansWE. Pharmacogenomics in the clinic. Nature526(7573), 343–350 (2015).
   PubMed Web of Science ®Google Scholar
• Bykov VJN , ErikssonSE , BianchiJ , WimanKG. Targeting mutant p53 for efficient cancer therapy. Nat. Rev. Cancer18(2), 89–102 (2018).
   PubMed Web of Science ®Google Scholar
• World Health Organisation . WHO cancer fact sheet. (2018). https://www.who.int/news-room/fact-sheets/detail/cancer
   Google Scholar
• Magid Diefenbach CS , DisisML , KeedyVet al. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J. Clin. Oncol.37(10), 834–849 (2019).
   PubMed Web of Science ®Google Scholar
• US FDA . Table of pharmacogenomic biomarkers in FDA drug labeling. (2019). https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
   Google Scholar
• Shekhani R , SteinacherL , SwenJJ , Ingelman-SundbergM. Evaluation of current regulation and guidelines of pharmacogenomic drug labels: opportunities for improvements. Clin. Pharmacol. Ther.107(5), 1240–1255 (2020).
   PubMed Web of Science ®Google Scholar
• PharmGKB . PharmGKB drug label information and legend. (2020). https://www.pharmgkb.org/page/drugLabelLegend
   Google Scholar
• Mehta D , UberR , IngleTet al. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine. Drug Discov. Today25(5), 813–820 (2020).
   PubMed Web of Science ®Google Scholar
• Huddart R , GongL , SangkuhlKet al. Response to: unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. Pharmacol. Res.158, 104838 (2020).
   PubMed Web of Science ®Google Scholar
• Koutsilieri S , TzioufaF , SismanoglouDC , PatrinosGP. Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. Pharmacol. Res.153, 104590 (2020).
   PubMed Web of Science ®Google Scholar
• Albassam A , AlshammariS , KoshyS , AwadA , OudaG. Knowledge, perceptions and confidence of physicians and pharmacists towards pharmacogenetics practice in Kuwait. PLoS ONE13(9), (2018).
   PubMed Web of Science ®Google Scholar
• Elewa H , AlkhiyamiD , AlsahanDet al. A survey on the awareness and attitude of pharmacists and doctors towards the application of pharmacogenomics and its challenges in Qatar. J. Eval. Clin. Pract.21(4), 703–709 (2015).
   PubMed Web of Science ®Google Scholar
• Abdela OA , BhagavathulaAS , GebreyohannesEA , TegegnHG. Ethiopian health care professionals’ knowledge, attitude, and interests toward pharmacogenomics. Pharmgenomics. Pers. Med.10, 279–285 (2017).
   PubMed Web of Science ®Google Scholar
• Yau A , AbdAziz AB , HaqueM. A systematic review of knowledge, attitude and practice towards pharmacogenomics among doctors ADAMU. Int. J. Pharm. Res.7(3), 145–154 (2015).
   Google Scholar
• Nagy M , LynchM , KamalSet al. Assessment of healthcare professionals’ knowledge, attitudes, and perceived challenges of clinical pharmacogenetic testing in Egypt. Per. Med.17(4), 251–260 (2020).
   PubMed Web of Science ®Google Scholar
• Relling MV , SchwabM , Whirl-carrilloMet al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT 15 genotypes: 2018 update. Clin. Pharmacol. Ther.105(5), 1–11 (2019).
   Web of Science ®Google Scholar
• Zaza G , CheokM , KrynetskaiaNet al. Thiopurine pathway. Pharmacogenet. Genomics.20(9), 573–574 (2010).
   PubMed Web of Science ®Google Scholar
• Ji Y . Applications of pharmacogenomics in oncology. Adv. Mol. Pathol.1(1), 115–124 (2018).
   Google Scholar
• Relling MV , HancockML , RiveraGKet al. Mercaptopurine therapy intolerance and heterozygosity. J. Natl Cancer Inst.91(23), 2001–2008 (2001).
   Google Scholar
• Evans WE . Pharmacogenetics of thiopurine s-methyltransferase and thiopurine therapy. Drug Monit.26(2), 186–191 (2004).
   PubMed Web of Science ®Google Scholar
• Dean L . Azathioprine therapy and TPMT genotype. Med. Genet. Summ.1–7 (2012). http://www.ncbi.nlm.nih.gov/pubmed/28520349
   Google Scholar
• Song K , JungY , ParkS-Ket al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat. Genet.46(9), 1017–1020 (2014).
   PubMed Web of Science ®Google Scholar
• Nielsen SN , GrellK , NerstingJet al. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a Phase III trial. Lancet. Oncol.18(4), 515–524 (2017).
   PubMed Web of Science ®Google Scholar
• Swen JJ , NijenhuisM , DeBoer Aet al. Pharmacogenetics: from bench to byte an update of guidelines. Clin. Pharmacol. Ther.89(5), 662–673 (2011).
   PubMed Web of Science ®Google Scholar
• The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group . DPWG guideline for mercaptopurine and NUDT15 [Internet]. 8/2019. https://www.pharmgkb.org/gene/PA134963132/guidelineAnnotation/PA166184613
   Google Scholar
• Relling MV , GardnerEE , SandbornWJet al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther.89(3), 387–391 (2011).
   PubMed Web of Science ®Google Scholar
• Schmiegelow K , RellingMV , SteinCMet al. Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Ther.93(4), 324–325 (2013).
   PubMed Web of Science ®Google Scholar
• Bank PCD , CaudleKE , SwenJJet al. Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clin. Pharmacol. Ther.103(4), 599–618 (2018).
   PubMed Web of Science ®Google Scholar
• The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group . Annotation of DPWG Guideline for mercaptopurine and TPMT]. 8/2019. https://www.pharmgkb.org/guidelineAnnotation/PA166104952
   Google Scholar
• PharmGKB . Drug label annotations for mercaptopurine, azathiopurine, thioguanine and TPMT. (2020). https://www.pharmgkb.org/gene/PA356/labelAnnotation
   Google Scholar
• PharmGKB . Drug label annotations for mercaptopurine, azathiopurine,thioguanine and NUDT15. (2020). https://www.pharmgkb.org/gene/PA134963132/labelAnnotation
   Google Scholar
• Chu E , DeVitaVT. Physicians’ cancer chemotherapy drug manual 2015. Jones & Bartlett Learning (2015). https://rudiapt.files.wordpress.com/2017/11/physicians-cancer-chemotherapy-drug-manual-2015.pdf
   Google Scholar
• Heggie GD , SommadossiJP , CrossDS , HusterWJ , DiasioRB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res.47(8), 2203–2206 (1987).
   PubMed Web of Science ®Google Scholar
• van Kuilenburg ABP . Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer40(7), 939–950 (2004).
   PubMed Web of Science ®Google Scholar
• Bertholee D , MaringJG , van KuilenburgABP. Genotypes affecting the pharmacokinetics of anticancer drugs. Clin. Pharmacokinet.56(4), 317–337 (2017).
   PubMed Web of Science ®Google Scholar
• Amstutz U , HenricksLM , OfferSMet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin. Pharmacol. Ther.103(2), 210–216 (2018).
   PubMed Web of Science ®Google Scholar
• Lunenburg CATC , vander Wouden CH , NijenhuisMet al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur. J. Hum. Genet. (1), (2019). http://www.ncbi.nlm.nih.gov/pubmed/31745289
   PubMedGoogle Scholar
• Clinical Pharmacogenetics Implementation Consortium (CPIC®) . November 2018 Update on the CPIC November 2017 DPD and fluoropyrimidines Guideline. (2018). https://www.pharmgkb.org/gene/PA145/guidelineAnnotation/PA166109594
   Google Scholar
• Henricks LM , LunenburgCATC , de ManFMet al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol.19(11), 1459–1467 (2018).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency . EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. ((2020). https://www.ema.europa.eu/en/news/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine
   Google Scholar
• PharmGKB . Drug label annotations for fluoropyrimidines and DPYD. https://www.pharmgkb.org/gene/PA145/labelAnnotation
   Google Scholar
• American Cancer Society . Cancer facts and figures 2019.. CA Cancer J. Clin. (2019). https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf
   Google Scholar
• Wilson BS , TucciDL , MersonMH , O’DonoghueGM. Global hearing health care: new findings and perspectives. Lancet390(10111), 2503–2515 (2017).
   PubMed Web of Science ®Google Scholar
• Shaloam D , TchounwouPB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol.740(1), 364–378 (2014).
   PubMedGoogle Scholar
• Tserga E , NandwaniT , EdvallNKet al. The genetic vulnerability to cisplatin ototoxicity: a systematic review. Sci. Rep.9(1), 3455 (2019).
   PubMedGoogle Scholar
• Bhavsar AP , GunaretnamEP , LiY , HasbullahJS , CarletonBC , RossCJD. Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines. PLoS ONE12(4), 1–10 (2017).
   Web of Science ®Google Scholar
• Siddik ZH . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene22(47), 7265–7279 (2003).
   PubMed Web of Science ®Google Scholar
• Ross CJD , Katzov-EckertH , DubeM-Pet al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet.41(12), 1345–1349 (2009).
   PubMed Web of Science ®Google Scholar
• Yancey A , HarrisMS , EgbelakinA , GilbertJ , PisoniDB , RenbargerJ. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr. Blood Cancer59(1), 144–148 (2012).
   PubMed Web of Science ®Google Scholar
• Grondin Y , BortoniME , SepulvedaRet al. Genetic polymorphisms associated with hearing threshold shift in subjects during first encounter with occupational impulse noise. PLoS ONE10(6), e0130827 (2015).
   PubMed Web of Science ®Google Scholar
• Yang JJ , LimJYS , HuangJet al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin. Pharmacol. Ther.94(2), 252–259 (2013).
   PubMed Web of Science ®Google Scholar
• Thiesen S , YinP , JorgensenALet al. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Pharmacogenet. Genomics27(6), 213–222 (2017).
   PubMed Web of Science ®Google Scholar
• Lee JW , PussegodaK , RassekhSRet al. Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using pharmacogenetic markers. Ther. Drug Monit.38(4), 423–431 (2016).
   PubMed Web of Science ®Google Scholar
• Packer RJ , GajjarA , VezinaGet al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol.24(25), 4202–4208 (2006).
   PubMed Web of Science ®Google Scholar
• Perilongo G , ShaffordE , MaibachRet al. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology–SIOPEL 2. Eur. J. Cancer40(3), 411–421 (2004).
   PubMed Web of Science ®Google Scholar
• Katzenstein HM , LondonWB , DouglassECet al. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J. Clin. Oncol.20(16), 3438–3444 (2002).
   PubMed Web of Science ®Google Scholar
• Brock PR , MaibachR , ChildsMet al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N. Engl. J. Med.378(25), 2376–2385 (2018).
   PubMed Web of Science ®Google Scholar
• Stern JW , BuninN. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med. Pediatr. Oncol.39(3), 163–167 (2002).
   PubMedGoogle Scholar
• Mann JR , RaafatF , RobinsonKet al. The United Kingdom Children’s Cancer Study Group’s second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J. Clin. Oncol.18(22), 3809–3818 (2000).
   PubMed Web of Science ®Google Scholar
• Shaikh F , NathanPC , HaleJ , UlerykE , FrazierL. Is there a role for carboplatin in the treatment of malignant germ cell tumors? A systematic review of adult and pediatric trials. Pediatr. Blood Cancer.60(4), 587–592 (2013).
   PubMed Web of Science ®Google Scholar
• Kolinsky DC , HayashiSS , KarzonR , MaoJ , HayashiRJ. Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens. J. Pediatr. Hematol. Oncol.32(2), 119–123 (2010).
   PubMed Web of Science ®Google Scholar
• PharmGKB . Drug label annotation for cisplatin and TPMT. (2020). https://www.pharmgkb.org/chemical/PA449014/labelAnnotation
   Google Scholar
• Noone AM , HowladerN , KrapchoMet al. SEER cancer statistics review, 1975–2015, Childhood Cancer by By International Classification of Childhood Cancer (ICCC). Natl Cancer Institute (2020). https://seer.cancer.gov/csr/1975_2015/
   Google Scholar
• Lipshultz SE , AlvarezJA , ScullyRE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart94(4), 525–533 (2008).
   PubMed Web of Science ®Google Scholar
• Scully RE , LipshultzSE. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc. Toxicol.7(2), 122–128 (2007).
   PubMed Web of Science ®Google Scholar
• Kremer LCM , vander Pal HJH , OffringaM , van DalenEC , VoutePA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann. Oncol.13(6), 819–829 (2002).
   PubMed Web of Science ®Google Scholar
• van der Pal HJ , van DalenEC , HauptmannMet al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch. Intern. Med.170(14), 1247–1255 (2010).
   PubMedGoogle Scholar
• Hershman DL , ShaoT. Anthracycline cardiotoxicity after breast cancer treatment. Oncology (Williston Park)23(3), 227–234 (2009).
   PubMed Web of Science ®Google Scholar
• Von Hoff DD , LayardMW , BasaPet al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med.91(5), 710–717 (1979).
   PubMed Web of Science ®Google Scholar
• Lefrak EA , PithaJ , RosenheimS , GottliebJA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer32(2), 302–314 (1973).
   PubMed Web of Science ®Google Scholar
• Felker GM , ThompsonRE , HareJMet al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med.342(15), 1077–1084 (2000).
   PubMed Web of Science ®Google Scholar
• Kremer LC , van DalenEC , OffringaM , OttenkampJ , VoutePA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J. Clin. Oncol.19(1), 191–196 (2001).
   PubMed Web of Science ®Google Scholar
• Rodvold KA , RushingDA , TewksburyDA. Doxorubicin clearance in the obese. J. Clin. Oncol.6(8), 1321–1327 (1988).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , LipsitzSR , MoneSMet al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med.332(26), 1738–1743 (1995).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , ColanSD , GelberRD , Perez-AtaydeAR , SallanSE , SandersSP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med.324(12), 808–815 (1991).
   PubMed Web of Science ®Google Scholar
• Aminkeng F , RossCJD , RassekhSRet al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br. J. Clin. Pharmacol.82(3), 683–695 (2016).
   PubMed Web of Science ®Google Scholar
• Olson RD , MushlinPS , BrennerDEet al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Natl Acad. Sci. USA85(10), 3585–3589 (1988).
   PubMed Web of Science ®Google Scholar
• Boucek RJJ , OlsonRD , BrennerDE , OgunbunmiEM , InuiM , FleischerS. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J. Biol. Chem.262(33), 15851–15856 (1987).
   PubMed Web of Science ®Google Scholar
• Mushlin PS , CusackBJ , BoucekRJJ , AndrejukT , LiX , OlsonRD. Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br. J. Pharmacol.110(3), 975–982 (1993).
   PubMed Web of Science ®Google Scholar
• Mordente A , MeucciE , SilvestriniA , MartoranaGE , GiardinaB. New developments in anthracycline-induced cardiotoxicity. Curr. Med. Chem.16(13), 1656–1672 (2009).
   PubMed Web of Science ®Google Scholar
• Minotti G , MennaP , SalvatorelliE , CairoG , GianniL. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev.56(2), 185–229 (2004).
   PubMed Web of Science ®Google Scholar
• Kremer LCM , van DalenEC , OffringaM , VoutePA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann. Oncol.13(4), 503–512 (2002).
   PubMed Web of Science ®Google Scholar
• Gottdiener JS , AppelbaumFR , FerransVJ , DeisserothA , ZieglerJ. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch. Intern. Med.141(6), 758–763 (1981).
   PubMed Web of Science ®Google Scholar
• Krischer JP , EpsteinS , CuthbertsonDD , GoorinAM , EpsteinML , LipshultzSE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J. Clin. Oncol.15(4), 1544–1552 (1997).
   PubMed Web of Science ®Google Scholar
• Barry E , AlvarezJA , ScullyRE , MillerTL , LipshultzSE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin. Pharmacother.8(8), 1039–1058 (2007).
   PubMed Web of Science ®Google Scholar
• Tukenova M , GuiboutC , OberlinOet al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J. Clin. Oncol.28(8), 1308–1315 (2010).
   PubMed Web of Science ®Google Scholar
• Aminkeng F , BhavsarAP , VisscherHet al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat. Genet.47(9), 1079–1084 (2015).
   PubMed Web of Science ®Google Scholar
• Visscher H , RossCJD , RassekhSRet al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr. Blood Cancer60(8), 1375–1381 (2013).
   PubMed Web of Science ®Google Scholar
• Visscher H , RossCJD , RassekhSRet al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol.30(13), 1422–1428 (2012).
   PubMed Web of Science ®Google Scholar
• Cascales A , Sanchez-VegaB , NavarroNet al. Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation. Int. J. Cardiol.154(3), 282–286 (2012).
   PubMed Web of Science ®Google Scholar
• Volkan-Salanci B , AksoyH , KiratliPOet al. The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms. J. Chemother.24(5), 285–291 (2012).
   PubMed Web of Science ®Google Scholar
• Armenian SH , DingY , MillsGet al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br. J. Haematol.163(2), 205–213 (2013).
   PubMed Web of Science ®Google Scholar
• Semsei AF , ErdelyiDJ , UngvariIet al. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol. Int.36(1), 79–86 (2012).
   PubMed Web of Science ®Google Scholar
• Visscher H , RassekhSR , SandorGSet al. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics16(10), 1065–1076 (2015).
   PubMed Web of Science ®Google Scholar
• Nagasawa K , NagaiK , OhnishiN , YokoyamaT , FujimotoS. Contribution of specific transport systems to anthracycline transport in tumor and normal cells. Curr. Drug Metab.2(4), 355–366 (2001).
   PubMed Web of Science ®Google Scholar
• Reichwagen A , ZiepertM , KreuzMet al. Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma. Pharmacogenomics16(4), 361–372 (2015).
   PubMed Web of Science ®Google Scholar
• Vulsteke C , PfeilAM , MaggenCet al. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. Breast Cancer Res. Treat.152(1), 67–76 (2015).
   PubMed Web of Science ®Google Scholar
• Bock KW , KohleC. UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects. Methods Enzymol.400, 57–75 (2005).
   PubMed Web of Science ®Google Scholar
• Krishnaswamy S , HaoQ , Al-RohaimiAet al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J. Pharmacol. Exp. Ther.313(3), 1340–1346 (2005).
   PubMed Web of Science ®Google Scholar
• Nagar S , ZalatorisJJ , BlanchardRL. Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics14(8), 487–499 (2004).
   PubMedGoogle Scholar
• PharmGKB . Drug label annotations for daunorubicin, doxorubicin and RARG, SLC28A3, UGT1A6. (2020). https://www.pharmgkb.org/chemical/PA449412/labelAnnotation
   Google Scholar
• Pasternak AL , LuzumJA , EllingrodVL , WardKM , HertzDL. Germline genetic variants with implications for disease risk and therapeutic outcomes. Physiol. Genomics49(10), 567–581 (2017).
   PubMed Web of Science ®Google Scholar
• Barbarino JM , HaidarCE , KleinTE , AltmanRB. PharmGKB summary: very important pharmacogene information for UGT1A1. Pharmacogenet. Genomics24(3), 177–183 (2014).
   PubMed Web of Science ®Google Scholar
• The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group . DPWG Guideline for irinotecan and UGT1A1 [Internet]. https://www.pharmgkb.org/guidelineAnnotation/PA166104951
   Google Scholar
• Guo C , GuoQ , GongYet al. The C677T mutation in the methylenetetrahydrofolate reductase gene and its association with deep vein thrombophilia in Shandong Hans. Chinese J. Med. Genet.19(4), 295–297 (2002).
   Google Scholar
• PharmGKB . Drug label annotations for irinotecan and UGT1A1. https://www.pharmgkb.org/chemical/PA450085/labelAnnotation/PA166104831
   Google Scholar
• Goetz MP , SangkuhlK , GuchelaarH-Jet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin. Pharmacol. Ther.103(5), 770–777 (2018).
   PubMed Web of Science ®Google Scholar
• Cole MP , JonesCT , ToddID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br. J. Cancer25(2), 270–275 (1971).
   PubMed Web of Science ®Google Scholar
• Davies C , GodwinJ , GrayRet al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (London, England).378(9793), 771–784 (2011).
   PubMed Web of Science ®Google Scholar
• Jordan VC . Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res. Treat.2(2), 123–138 (1982).
   PubMedGoogle Scholar
• Barginear MF , JaremkoM , PeterIet al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin. Pharmacol. Ther.90(4), 605–611 (2011).
   PubMed Web of Science ®Google Scholar
• van Schaik RHN . Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest. New Drugs23(6), 513–522 (2005).
   PubMed Web of Science ®Google Scholar
• Drogemoller BI , WrightGEB , ShihJet al. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. Breast Cancer Res. Treat.173(3), 521–532 (2019).
   PubMed Web of Science ®Google Scholar
• The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group . DPWG guideline for tamoxifen and CYP2D6. (2020). https://www.pharmgkb.org/guidelineAnnotation/PA166104966
   Google Scholar
• PharmGKB . Drug label annotations for tamoxifen and CYP2D6. (2020). https://www.pharmgkb.org/chemical/PA451581/labelAnnotation
   Google Scholar
• Caudle KE , SangkuhlK , Whirl-CarrilloMet al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin. Transl. Sci.1–9 (2019). http://www.ncbi.nlm.nih.gov/pubmed/31647186
   Web of Science ®Google Scholar